Once again in 2005, large pharma and biotech companies increased their appetite for partnerships and alliances to fuel early stage and late stage pipeline requirements. Overall, mid and late stage deals extended the trend of the last few years representing about half of all biotech out-licensing de...(Full transcript available to logged in subscribers.).
Register & Subscribe
Login
